SCHEMBL333633

SCHEMBL333633

COC(=O)c1ccc(-c2c(C(=O)OC)c3cc(Oc4ccc(Cl)cc4)ccc3n2-c2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 2/20 0.44
MDM2 Q00987 2/20 0.44
MCL1 Q07820 2/20 0.44
USP14 P54578 3/20 0.42
MAPT P10636 4/20 0.41
MAPK1 P28482 2/20 0.41
HTT P42858 2/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.41
PTGS2 P35354 6/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335545 0.92 MDM2 (0.44) BCL2MDM2MCL1USP14MAPT
SCHEMBL334104 0.92 MDM2 (0.42) BCL2MDM2MCL1MAPTMAPK1
SCHEMBL333981 0.89 MDM2 (0.44) BCL2MDM2MCL1MAPTMAPK1
SCHEMBL333553 0.88 USP14 (0.45) BCL2MDM2MCL1USP14HPGD
SCHEMBL333729 0.88 MAPT (0.54) BCL2MDM2MCL1MAPTMAPK1
SCHEMBL28767827 0.87 USP14 (0.43) USP14MAPTMAPK1HTTPKM
SCHEMBL333886 0.80 RXRA (0.45) BCL2MDM2MCL1USP14KMT2A
SCHEMBL27717567 0.80 PPARG (0.41) BCL2MDM2MCL1USP14MAPT
SCHEMBL334015 0.80 KMT2A (0.43) BCL2MDM2MCL1USP14HPGD
SCHEMBL27717578 0.79 USP14 (0.45) USP14SMN1; SMN2PTGS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
EP-1841735-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-10-10 EP disclosed
WO-2006077366-A1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG BCL2 325/4885MDM2 917/4885MCL1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.